ATE286032T1 - Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen - Google Patents

Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen

Info

Publication number
ATE286032T1
ATE286032T1 AT98953969T AT98953969T ATE286032T1 AT E286032 T1 ATE286032 T1 AT E286032T1 AT 98953969 T AT98953969 T AT 98953969T AT 98953969 T AT98953969 T AT 98953969T AT E286032 T1 ATE286032 T1 AT E286032T1
Authority
AT
Austria
Prior art keywords
pharmaceutically acceptable
compositions containing
production
pharmaceutical compositions
heterocyclic compounds
Prior art date
Application number
AT98953969T
Other languages
English (en)
Inventor
Vidya Bhushan Lohray
Braj Bhushan Lohray
Rao Bheema Paraselli
Rajagopalan Ramanujam
Ranjan Chakrabarti
Original Assignee
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr
Application granted granted Critical
Publication of ATE286032T1 publication Critical patent/ATE286032T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/04—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98953969T 1998-04-23 1998-10-26 Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen ATE286032T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8282598P 1998-04-23 1998-04-23
PCT/US1998/022568 WO1999008501A2 (en) 1998-04-23 1998-10-26 New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
ATE286032T1 true ATE286032T1 (de) 2005-01-15

Family

ID=22173702

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98953969T ATE286032T1 (de) 1998-04-23 1998-10-26 Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen

Country Status (6)

Country Link
EP (1) EP1073643B1 (de)
CN (1) CN1208326C (de)
AT (1) ATE286032T1 (de)
AU (1) AU1120599A (de)
DE (1) DE69828445D1 (de)
WO (1) WO1999008501A2 (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020060067A (ko) * 1999-04-06 2002-07-16 가와무라 요시부미 α-치환 카르복실산 유도체
WO2000063189A1 (en) * 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
US7414128B2 (en) 1999-04-20 2008-08-19 Dr. Reddy's Laboratories, Limited Crystalline R-guanidines, Arginine or (L)-Arginine (2S)-2-Ethoxy-3-{4-[2-(10H -phenoxazin-10-yl)ethoxy]phenyl}propanoate
US6369055B1 (en) 1999-04-20 2002-04-09 Novo Nordisk A/S Compounds, their preparation and use
CN1348439A (zh) * 1999-04-20 2002-05-08 诺沃挪第克公司 新化合物及其制备和用途
EP1171438A1 (de) * 1999-04-20 2002-01-16 Novo Nordisk A/S Verbindungen, ihre herstellung und ihre verwendung
EP1171431A1 (de) * 1999-04-20 2002-01-16 Novo Nordisk A/S Verbindungen, ihre anwendung und ihre verwendung
US6972294B1 (en) 1999-04-20 2005-12-06 Novo Nordisk, A/S Compounds, their preparation and use
EP1177187B1 (de) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl-säurederivate als ppar rezeptor liganden
WO2000064876A1 (en) 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Tri-aryl acid derivatives as ppar receptor ligands
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
CN1266129C (zh) * 2000-01-19 2006-07-26 卡地拉健康护理有限公司 具有降血脂和降低血中胆固醇活性的新化合物、其制备方法和含有它们的药物组合物
EP1741445B1 (de) 2000-01-21 2013-08-14 Novartis AG Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
KR20020070508A (ko) * 2000-01-28 2002-09-09 노보 노르디스크 에이/에스 프로피온산 유도체 및 당뇨병 및 비만의 치료에 그것의 사용
US6555577B1 (en) 2000-01-28 2003-04-29 Novo Nordisk A/S Compounds, their preparation and use
US6509374B2 (en) 2000-04-17 2003-01-21 Novo Nordisk A/S Compounds, their preparation and use
EP1939203B1 (de) * 2000-04-25 2014-11-19 ICOS Corporation Hemmer der delta-Isoform der menschlichen Phosphatidyl-Inositol-3-Kinase
MXPA02010618A (es) * 2000-04-25 2004-05-05 Icos Corp Inhibidores de fosfatidilinositol 3-quinasa delta.
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
UA82048C2 (uk) 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
JP4711600B2 (ja) 2001-01-26 2011-06-29 シェーリング コーポレイション シトステロール血症の処置のための置換アゼチジノン化合物の使用
SI1413331T1 (sl) * 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
WO2002062798A2 (en) * 2001-02-05 2002-08-15 Dr. Reddy's Laboratories Ltd. Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
CA2436741A1 (en) * 2001-02-05 2002-08-15 Dr. Reddy's Laboratories Limited Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents
WO2002081454A1 (en) * 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
DE60211891T2 (de) 2001-05-15 2007-05-24 F. Hoffmann-La Roche Ag Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes
JP2004530728A (ja) * 2001-06-28 2004-10-07 ドクター・レディーズ・ラボラトリーズ・リミテッド ３−アリール−α−オキシ置換プロパン酸およびそれらの製造方法
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
KR20040044515A (ko) * 2001-08-29 2004-05-28 워너-램버트 캄파니 엘엘씨 경구용 항당뇨병제
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7220877B2 (en) 2001-10-17 2007-05-22 Novo Nordisk A/S Compounds, their preparation and use
JP2005518408A (ja) 2001-12-29 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ 異常脂肪血症を治療するための、ｇｌｐ−１化合物と他の薬物との組み合わせ使用
WO2003070701A2 (en) 2002-02-15 2003-08-28 Cytokinetics, Inc. Syntheses of quinazolinones
US7015345B2 (en) 2002-02-21 2006-03-21 Asahi Kasei Pharma Corporation Propionic acid derivatives
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
WO2003094839A2 (en) 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
AU2003270015A1 (en) 2002-05-09 2003-12-02 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005536475A (ja) 2002-05-23 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
EP1556357A4 (de) 2002-06-14 2006-09-13 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
JP4290648B2 (ja) 2002-07-03 2009-07-08 エフ．ホフマン−ラ ロシュ アーゲー オキサゾール誘導体及びインスリン感作物質としてのそれらの使用
WO2004004665A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
EP1537089A4 (de) 2002-07-23 2008-04-16 Cytokinetics Inc Verbindungen, zusammenstellungen und verfahren
PL375779A1 (en) 2002-08-30 2005-12-12 F.Hoffmann-La Roche Ag Novel 2-arylthiazole compounds as pparalpha and ppargamma agonists
EP1539746B1 (de) 2002-09-12 2006-11-15 F. Hoffmann-La Roche Ag N-substituierte-1h-indol-5-propansäure verbindungen als ppar-agonisten zur behandlung von diabetis
EP1558083A4 (de) 2002-09-30 2008-04-16 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
TW200408393A (en) 2002-10-03 2004-06-01 Ono Pharmaceutical Co Antagonist of lysophosphatidine acid receptor
CA2504878A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
MXPA05005445A (es) 2002-11-25 2005-08-26 Hoffmann La Roche Derivados de indolilo.
US7816385B2 (en) 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
CN100439361C (zh) 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
JP2007513154A (ja) 2003-12-08 2007-05-24 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
WO2005100318A1 (en) * 2004-04-14 2005-10-27 Ranbaxy Laboratories Limited Alkanoic acids and their esters as antidiabetic agents
PL1761540T3 (pl) 2004-05-13 2017-06-30 Icos Corporation Chinazolinony jako inhibitory ludzkiej kinazy 3-fosfatydyloinozytolu delta
US20080114005A1 (en) * 2004-09-06 2008-05-15 Dr. Reddy's Laboratories Limited Fibrate Compounds Having Ppar Agonist Activity
CA2622608C (en) 2005-09-14 2014-08-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
NZ631024A (en) 2008-11-13 2016-04-29 Gilead Calistoga Llc Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
SG174529A1 (en) 2009-03-24 2011-10-28 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
EP2456443A1 (de) 2009-07-21 2012-05-30 Gilead Calistoga LLC Behandlung von lebererkrankungen mit pi3k-hemmern
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
SI2531501T1 (sl) 2010-02-03 2014-04-30 Takeda Pharmaceutical Company Limited Inhibitorji kinaze-1, ki regulirajo signal apoptoze
CN103354757A (zh) 2011-01-31 2013-10-16 卡迪拉保健有限公司 脂肪代谢障碍的治疗
AP2014007875A0 (en) 2012-03-05 2014-08-31 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
EP2988736A1 (de) 2013-04-22 2016-03-02 Cadila Healthcare Limited Neuartige zusammensetzung für nicht alkoholbedingte fettlebererkrankung (nafld)
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (de) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (de) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
EP3083623A1 (de) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphe formen eines hydrochloridsalzes aus (s)-2-(9h-purin-6-ylamino)propyl)-5-fluor-3-phenylchinazolin-4 (3h)-on
PT3083630T (pt) 2013-12-20 2019-11-15 Gilead Calistoga Llc Procedimentos para inibidores da fosfatidilinositol 3-quinase
JP6455995B2 (ja) 2014-06-13 2019-01-23 ギリアード サイエンシーズ， インコーポレイテッド ホスファチジルイノシトール３−キナーゼ阻害剤
MX389591B (es) 2014-08-29 2025-03-20 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
EP3253759A1 (de) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Isothiazolpyrimidinone, pyrazolopyrimidinone und pyrrolopyrimidinone als ubiquitin-spezifische protease-7-hemmer
JP2018504431A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのチエノピリミジノン
JP2018504430A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのキナゾリノン及びアザキナゾリノン
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
KR102678264B1 (ko) 2015-12-04 2024-06-24 브리스톨-마이어스 스큅 컴퍼니 아펠린 수용체 효능제 및 사용 방법
CN105777744A (zh) * 2016-03-07 2016-07-20 程盼盼 一种降血糖的药物组合物
WO2018104916A1 (en) 2016-12-09 2018-06-14 Cadila Healthcare Limited Treatment for primary biliary cholangitis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL174610B1 (pl) * 1992-07-03 1998-08-31 Smithkline Beecham Plc Nowe związki heterocykliczne
RU2200161C2 (ru) * 1996-12-31 2003-03-10 Др. Редди'З Рисерч Фаундейшн Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение

Also Published As

Publication number Publication date
WO1999008501A3 (en) 1999-04-15
WO1999008501A2 (en) 1999-02-25
DE69828445D1 (de) 2005-02-03
EP1073643B1 (de) 2004-12-29
EP1073643A2 (de) 2001-02-07
CN1208326C (zh) 2005-06-29
CN1280571A (zh) 2001-01-17
AU1120599A (en) 1999-03-08

Similar Documents

Publication Publication Date Title
ATE286032T1 (de) Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
YU60701A (sh) Nova triciklička jedinjenja i njihova upotreba u medicini; postupak za njihovo pripremanje i farmaceutske kompozicije koje ih sadrže
IL127296A0 (en) Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
DE60239939D1 (de) Neue pyrrole mit hypolipidämischer und hypocholesterischer aktivität, herstellungsverfahren, diese enthaltende pharmazeutische zusammensetzungen und deren medizinische verwendung
NZ504106A (en) Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them
CA2258949A1 (en) Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
MY121760A (en) Benzothiazin and benzoxazin derivatives;their preparation and uses
ATE156835T1 (de) Neue 11-benzaldoximestradien-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ATE154013T1 (de) Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
YU52403A (sh) Heterociklična jedinjenja koja imaju antibakterijsko dejstvo, postupak za njihovo dobijanje i farmaceutske smeše koje ih sadrže
DE3581566D1 (de) Oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte.
ATE302778T1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
BG106932A (en) Novel compounds having hypolipedemic and hypocholesteremic activities, processes for their preparation and pharmaceutical compositions containing them
ATE149513T1 (de) Neue 11-benzaldoxim-17beta methoxy-17alpha- methoxymethyl-estradien-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
WO2001090097A3 (en) Novel compounds having antiinflammatory activity: process for their preparation and pharmaceutical compositions containing them
AU656466B2 (en) New benzimidazole compounds, a process for their preparation and pharmaceutical compositions containing them
ES2036926A1 (es) "procedimiento para la obtencion de derivados de la (2-alquil-3-piridil)metilpiperazina".
ATE247645T1 (de) Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung
MY130757A (en) Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
ATE172976T1 (de) 3-aminochroman-spiroderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
SE9103022D0 (sv) Nya 5h-bensodiazepinderivat, farmaceutiska kompositioner innehaallande desamma samt foerfarande foer framstaellning av dessa
ATE343580T1 (de) Tetracyclische arylcarbonyl indole mit serotoninrezeptoraffinität als arzneimittel, verfahren zu ihrer herstellung und pharmazeutische zubereitungen
DE60041137D1 (de) Ceramid ähnliche verbindungen, verfahren zu deren herstellung und deren verwendung als antitumormittel
DE59606725D1 (de) Substituierte phenylamidine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE69417907D1 (de) Anthracyclin-disaccharide, verfahren zu ihrer herstellung, und diese enthaltende arzneimittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties